AI Governance
Connecticut’s health-plan AI policy limits sole AI decisions, restricts member-data use for other AI models, and adds disclosure, validation, and governance requirements.
AI Governance
The CSBS AI Supervisory Framework gives state examiners a clearer approach to AI oversight. See what it covers, how it differs from federal model-risk guidance, and what financial institutions should review.
AI Regulation
Attorney General Todd Blanche says DOJ will not pursue “regulation by prosecution” against AI companies absent a statutory violation. Existing employment and consumer-protection laws can still apply when AI is involved.
Health Data
ChatGPT Health can receive patient-directed health data outside HIPAA’s framework. Here’s what HHS, FTC rules, and state privacy laws mean for governance teams.
AI Disclosures
AI-related cases were a minority of H1 2026 securities filings but accounted for 73% of two major market-loss measures. Here’s what the numbers mean for boards, GCs, disclosure teams, IR, and AI leaders.
AI Regulation
Twelve states regulate companion bots through differing disclosure, minor-safety, crisis-response, and other requirements. This analysis separates recurring governance patterns from state-specific rules in California, Colorado, and beyond.
AI safety policy
Anthropic and OpenAI disclosed separate AI safety incidents during cyber evaluations. For enterprise leaders, the question is shifting from safety promises to evidence that controls, monitoring, and containment work under stress.
Cybersecurity Risk
Recent 2026 breach data shows AI spreading across attack techniques while familiar vulnerabilities remain major entry points. Here’s what security leaders should treat as foundational now.
AI Governance
AI scribes offer documentation benefits, but research also finds omissions, hallucinations, and other note errors. The key governance question is what clinically consequential defects remain after clinician review.
Pharmacy Benefit Management
Florida’s PBM lawsuit against Prime Therapeutics and Express Scripts raises a larger oversight question: who controls pharmacy reimbursement, and can plan sponsors trace reported savings to net plan economics?
Medicaid policy
Nine more drugmakers have joined Trump’s MFN pricing push. Here’s how Medicaid participation, rebates, tariffs, and onshoring conditions shape the implementation test.
Bond market
High sovereign yields do not automatically signal a buyers’ strike. See what SF Fed term-premium data, Treasury financing plans, and Japan’s latest 10-year auction actually show.